Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death

Cancer Letters

Volumn 287, Issue 2, 2010, Pages 216-223

  Martín, Vanesa ^a,b   García Santos, Guillermo ^a,b   Rodriguez Blanco, Jezabel ^a   Casado Zapico, Sara ^a,b   Sanchez Sanchez, Ana ^a   Antolín, Isaac ^a   Medina, Maria ^b,c,d   Rodriguez, Carmen ^a,b  

^a Departamento de Morfologia y Biología Celular   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c Facultad de Medicina   (Spain)

^d HOSPITAL DE JOVE   (Spain)

Author keywords

Apoptosis; Death receptors; Glioma; Melatonin; TRAIL

Indexed keywords

DEATH RECEPTOR 5; MELATONIN; PROTEIN BCL 2; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVITY; GLIOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; GLIOMA; HUMANS; MELATONIN; MICROTUBULE-ASSOCIATED PROTEINS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 72949118848     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.016     Document Type: Article

References (40)

1. Gurney J.G., and Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr. Opin. Oncol. 13 (2001) 160-166
2. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5 (1999) 157-163
3. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., Deforge L., Pai R., Hymowitz S.G., and Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280 (2005) 2205-2212
4. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12 (1991) 151-180
5. Vanecek J. Cellular mechanisms of melatonin action. Physiol. Rev. 78 (1998) 687-721
6. Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 56 (1998) 359-384
7. Tamarkin L., Cohen M., Rosell D., Reichert C., Lippman M., and Chabner B. Melatonin inhibition and pinealectomy enhancement of dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer. Res. 41 (1981) 4432-4436
8. Pierpaoli W., and Regelson W. Pineal control of aging: effect of melatonin and pineal grafting on aging mice. Proc. Natl. Acad. Sci. USA 91 (1994) 787-791
9. Cos S., Fernandez R., Guezmes A., and Sanchez-Barcelo E.J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer. Res. 58 (1998) 4383-4390
10. Moretti M.M., Limonta P., Maggi R., Motta M., and Moretti R.M. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate 45 (2000) 238-244
11. Sainz T.M., Mayo J.C., Tan D.X., Lopez-Burillo S., Natarajan M., and Reiter R.J. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochem. Biophys. Res. Commun. 302 (2005) 625-634
12. Martín V., Herrera F., Carrera-Gonzalez P., García-Santos G., Antolín I., Rodriguez-Blanco J., and Rodriguez C. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res. 66 (2006) 1081-1088
13. Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival. J. Inmunol. Methods 89 (1986) 271-277
14. Ciusani E., Croci D., Gelati M., Calatozzolo C., Sciacca F., Fumagalli L., Balzarotti M., Fariselli L., Boiardi A., and Salmaggi A. In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. J. Neurooncol. 71 (2005) 19-25
15. Jung B., and Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res. 66 (2006) 9789-9793
16. Srinivasan V., Spence D.W., Pandi-Perumal S.R., Trakht I., and Cardinali D.P. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr. Cancer Ther. 7 (2008) 189-203
17. Hill S.M., Teplitzky S., Ram P.T., Kiefer T., Blask D.E., Spriggs L.L., and Eck K.M. Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer. Adv. Exp. Med. Biol. 460 (1999) 345-362
18. Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol. Biol. (Paris) 55 (2007) 201-204
19. Maestroni G.J., Conti A., and Lissoni P. Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res. 54 (1994) 4740-4743
20. Fic M., Podhorska-Okolow M., Dziegiel P., Gebarowska E., Wysocka T., Drag-Zalesinska M., and Zabel M. Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). In Vivo 21 (2007) 513-518
21. Sainz R.M., Reiter R.J., Tan D.X., Roldan F., Natarajan M., Quiros I., Hevia D., Rodriguez C., and Mayo J.C. Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. J. Pineal Res. 45 (2008) 258-270
22. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 (2000) 611-620
23. Tomasetti M., Andera L., Alleva R., Borghi B., Neuzil J., and Procopio A. Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett. 580 (2006) 1925-1931
24. Delmas D., Rébé C., Micheau O., Athias A., Gambert P., Grazide S., Laurent G., Latruffe N., and Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23 (2004) 8979-8986
25. Jeon K.I., Rih J.K., Kim H.J., Lee Y.J., Cho C.H., Goldberg I.D., Rosen E.M., and Bae I. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line. LNCaP. FEBS Lett. 544 (2003) 246-251
26. Galluzzi L., Larochette N., Zamzami N., and Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25 (2006) 4812-4830
27. Hunter A.M., LaCasse E.C., and Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12 (2007) 1543-1568
28. Rodriguez-Pereira C., Suarez-Peñaranda J.M., Barros F., Sobrido M.J., Vazquez-Salvado M., and Forteza J. Analysis of 2 antiapoptotic factors in gliomas: bcl-2 overexpression and p53 mutations. Arch. Pathol. Lab. Med. 125 (2001) 218-223
29. Fulda S., Meyer E., and Debatin K.M. Inhibition of TRAIL-induced apoptosis by bcl-2 overexpression. Oncogene 21 (2002) 2283-2294
30. Hetschko H., Voss V., Horn S S., Seifert V., Prehn J.H., and Kögel D. Pharmacological inhibition of bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J. Neurooncol. 86 (2008) 265-272
31. Fortugno P., Beltrami E E., Plescia J., Fontana J., Pradhan D., Marchisio P.C., Sessa W.C., and Altieri D.C. Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 100 (2003) 13791-13796
32. Chakravarti A., Noll E., Black P.M., Finkelstein D.F., Finkelstein D.M., Dyson N.J., and Loeffler J.S. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20 (2002) 1063-1068
33. Falschlehner C., Emmerich C.H., Gerlach B., and Walczak H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 39 (2007) 1462-1475
34. Dasgupta P., Kinkade R., Joshi B., Decook C., Haura E., and Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc. Natl. Acad. Sci. USA 103 (2006) 6332-6337
35. Kim S., Kang J., Qiao J., Thomas R.P., Evers B.M., and Chung D.H. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J. Pediatr. Surg. 39 (2004) 516-521
36. David E., Sinha R., Chen J., Sun S.Y., Kaufman J.L., and Lonial S. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin. Cancer Res. 14 (2008) 5090-5098
37. Alladina S.J., Song J.H., Davidge S.T., Hao C., and Easton A.S. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and bcl-2. J. Vasc. Res. 42 (2005) 337-347
38. Martín V., Herrera F., García-Santos G., Antolín I., Rodriguez-Blanco J., Medina M., and Rodriguez C. Involvement of protein kinase C in melatonin's oncostatic effect in C6 glioma cells. J. Pineal. Res. 43 (2007) 239-244
39. Okhrimenko H., Lu W., Xiang C., Hamburger N., Kazimirsky G., and Brodie C. Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res. 65 (2005) 7301-7309
40. Okhrimenko H., Lu W., Xiang C., Ju D., Blumberg P.M., Gomel R., Kazimirsky G., and Brodie C. Roles of tyrosine phosphorylation and cleavage of protein kinase Cdelta in its protective effect against tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis. J. Biol. Chem. 280 (2005) 23643-23652